Strategic Vision: A Global Pharma Company
P&L Highlights- Q4 FY 2022
LUPIN
Amount in INR mn
Q4FY22
Q3FY22
Sales
Other operating income
Total revenue
38,645
185
38,830
% of
Sales
100.0% 40,875 100.0%
0.5% 734 1.8%
100.5% 41,609 101.8%
% of
QoQ
Sales Growth
% of
YOY
Q4FY21
Sales
Growth
-5.5% 37,593 100.0% 2.8%
-74.8% 238 0.6% -22.3%
-6.7% 37,831 100.6% 2.6%
Gross Profit
22,323
57.8% 23,929 58.5%
-6.7% 24,417 65.0% -8.6%
(excl. other operating income)
EBITDA¹
2,823
PBT before exceptional item 1/2
-864
7.3%
-2.2%
4,039 9.9%
1,671 4.1%
-30.1% 7,657
20.4% -63.1%
5,182 13.8%
Exceptional item
-12
0.0%
0
PBT after exceptional item
-852
-2.2%
1,671
0.0%
4.1%
0.0%
0.0%
5,182 13.8%
Profit after Tax
-5,119
-13.2%
5,491 13.4%
4,642 12.3%
Profit/(Loss) for the period
-5,180
-13.4%
5,455
13.3%
4,604
12.2%
1.
In Q3 FY22, other expenses include the impact of one-time expenses of INR 1,932 mn related to residual Metformin returns from retail and consumers not identified
previously, and a provision for aged stock returns of Oseltamivir given lack of an active flu season for the past two years.
2. Depreciation & Amortization & impairment expense of Q4 FY22 includes INR 1,267 mn on account of impairment of Gavis IPs.
10View entire presentation